TLDR
- Zoetis stock fell 20% to $88.94 on Thursday, its worst S&P 500 performance of the session
- Q1 EPS came in at $1.53, missing the $1.60 Wall Street estimate; revenue of $2.26B missed the $2.3B consensus
- The company cut full-year EPS guidance to $6.85–$7.00, down from $7.00–$7.10
- CEO cited increased pet owner price sensitivity and fewer vet visits as key headwinds
- Stifel analysts said results are “worse than it seems” due to a $100M revenue boost from a one-time fiscal realignment
Zoetis (ZTS) stock dropped 20% to $88.94 on Thursday, making it the worst performer in the S&P 500 for the session. According to Dow Jones Market Data, the stock is now on pace for its lowest close in over seven years, and is down 29% year-to-date.
The sell-off came after the animal health company reported first-quarter results that missed on both the top and bottom lines.
Q1 earnings came in at $1.53 per share, up from $1.48 a year ago but below the $1.60 Wall Street expected. Revenue grew 3% year-over-year to $2.26 billion, short of the $2.3 billion analyst consensus, per FactSet.
$ZTS | Zoetis Inc., Q1-2026 Earning Report pic.twitter.com/8Gd4ra4qok
— Hardik Shah (@AIStockSavvy) May 7, 2026
CEO Kristin Peck said the quarter played out in a tougher environment than the company had planned for. Pet owners pulled back on spending, leading to fewer vet visits and weaker demand for premium products.
U.S. revenue fell roughly 8% year-over-year to $1.1 billion. Companion animal product sales in the U.S. dropped about 11%, hit by softer demand and competition.
International Segment Offered Some Relief
International revenue grew 17% year-over-year to $1.1 billion, helped by a 10% rise in companion animal product sales. The parasiticides portfolio was a key driver of that growth.
However, that international number included an estimated $100 million in revenue pulled forward from a fiscal year alignment change. The company eliminated a one-month reporting lag for its overseas units, effectively boosting Q1 international results in a way that won’t repeat.
Analysts Say It’s Worse Than It Looks
Stifel analyst Jonathan Block and his team said the Q1 report is actually “worse than it seems.” Once that $100 million realignment benefit is stripped out, organic operational revenue growth came in well below consensus.
Block’s team pointed to “notable weakness” in the pet business segment as a particular concern.
Zoetis responded by cutting its 2026 full-year outlook. The company now expects adjusted EPS of $6.85 to $7.00, down from its prior range of $7.00 to $7.10. Wall Street had been modeling $7.03.
Full-year revenue guidance was also lowered to between $9.68 billion and $9.96 billion, from the previous range of $9.825 billion to $10.025 billion. The analyst consensus sat at $9.89 billion.
Peck said the company is taking “decisive action to sharpen commercial execution, unlock revenue, and continue to drive disciplined cost management.”
The stock’s 20% single-day drop now has ZTS sitting at levels not seen since early 2019.
Adjusted EPS of $1.53 reflected roughly 9% year-over-year growth, but still missed the consensus estimate by $0.09.
Thursday’s move puts the full-year decline at 29%, a tough stretch for a stock that was once considered a steady compounder in the healthcare space.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
